U.S. Tech Hardware Stock News

NYSE:BKU
NYSE:BKUBanks

A Look At BankUnited (BKU) Valuation After Solid Results And Slower Net Interest Income Growth

Recent commentary around BankUnited (BKU) focuses on its solid quarterly results, which have supported recent share price gains, while also highlighting slower net interest income growth and the possibility of a less efficient cost base ahead. See our latest analysis for BankUnited. At a latest share price of $46.70, the 1 day and 7 day share price returns of 5.62% and 6.73% declines contrast with a 90 day share price return of 8.08% and a 1 year total shareholder return of 28.47%. This...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Assessing Butterfly Network’s Valuation After Record Q4 Growth And First Positive Operating Cash Flow

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...
NYSE:OXY
NYSE:OXYOil and Gas

Is Occidental Petroleum (OXY) Pricing Reflect Long Term Value After Mixed Share Performance

If you are wondering whether Occidental Petroleum's current share price really reflects what you are getting for your money, this article walks through the numbers so you can judge the value for yourself. The stock last closed at US$53.08, with returns of 2.4% over 7 days, 18.4% over 30 days, 25.2% year to date, 11.1% over 1 year, negative 8.9% over 3 years and 80.4% over 5 years. This gives you a mixed picture to keep in mind as you weigh the valuation. Recent coverage of Occidental has...
NYSE:OTIS
NYSE:OTISMachinery

A Look At Otis Worldwide (OTIS) Valuation After Launch Of Arise MOD Elevator Modernization Packages

Otis Worldwide (OTIS) has introduced its Arise MOD Prime and Arise MOD Plus elevator modernization packages in North America, giving building owners more choice over how they update low to mid rise residential and commercial elevators. See our latest analysis for Otis Worldwide. At a share price of US$92.56, Otis has a 30 day share price return of 4.47%. Its 1 year total shareholder return shows a 5.52% decline, which contrasts with a 54.07% total shareholder return over five years and...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

American Bitcoin (ABTC) Revenue Surge With FY 2025 Loss Tests Bullish Growth Narratives

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Monster Beverage (MNST) Margin Expansion Reinforces Bull Narratives Despite Rich P/E

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...
NYSE:BRSL
NYSE:BRSLHospitality

Brightstar Lottery Board Shifts Test Capital Returns And Italy Growth Plan

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...
NYSE:FR
NYSE:FRIndustrial REITs

A Look At First Industrial Realty Trust’s Valuation After Land & Buildings’ Activist Letter And Board Challenge

Why the activist letter matters for First Industrial Realty Trust (FR) On February 26, Land & Buildings Investment Management publicly challenged First Industrial Realty Trust (FR), criticizing its boardroom culture and urging changes it says are needed to address the REIT’s trading discount and unlock more value. See our latest analysis for First Industrial Realty Trust. At a share price of US$63.14, First Industrial Realty Trust has logged an 11.03% 1 month share price return and a 14.42% 1...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Olema Pharmaceuticals (OLMA) Valuation Check After Recent Share Price Volatility

Olema Pharmaceuticals (OLMA) has been drawing attention after recent share price swings, with the stock at US$24.20 and mixed returns over the past month, past 3 months, and year to date, prompting fresh investor scrutiny. See our latest analysis for Olema Pharmaceuticals. While the recent 1 day and 30 day share price returns show modest declines from US$24.20, the very large 1 year and 3 year total shareholder returns suggest earlier optimism around Olema Pharmaceuticals is now being...
NYSE:ESTC
NYSE:ESTCSoftware

Elastic ESTC Swings To Q3 Profit Challenging Persistent Loss Making Narrative

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...
NYSE:BURL
NYSE:BURLSpecialty Retail

Burlington’s 2026 Expansion Plans Test Valuation And Debt Profile

Burlington Stores (NYSE:BURL) plans to open 110 net new stores in 2026, ahead of earlier expectations. The company is also expanding its corporate office footprint in New York to support a larger organization. These moves reflect management's intent to scale operations and reinforce Burlington's long term growth plans. Burlington Stores comes into this announcement with its shares at $306.62 and a 1 year return of 23.0%. Over 3 years the stock has returned 41.8%, and over 5 years 9.8%,...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Nutex Health (NUTX) Is Up 9.3% After Profitability And Valuation Analysis Sparks Investor Interest

Recent analysis of Nutex Health’s hybrid model of micro-hospitals, hospital management services, and population health programs highlighted strong profitability metrics and claims of deep undervaluation, drawing fresh investor attention in the past week. An interesting angle is the company’s high free cash flow conversion, which some commentators argue could support a meaningful reassessment of its valuation if operating performance holds. We’ll now examine how Nutex Health’s highlighted...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering

AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering. Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo Technologies (ARLO) Earnings Turn Positive Challenging Skeptical Profitability Narratives

Arlo Technologies (ARLO) closed out FY 2025 with Q4 revenue of US$141.3 million and basic EPS of US$0.05, alongside net income of US$5.8 million. The trailing 12 month line shows revenue of US$529.3 million and basic EPS of US$0.14 as the business moves further into consistent profitability. Over the past six quarters, the company has seen revenue range from US$119.1 million to US$141.3 million per quarter, with basic EPS shifting from a loss of US$0.05 in late 2024 to positive contributions...
NYSE:HLX
NYSE:HLXEnergy Services

Helix Energy Solutions Group (HLX) Valuation After Record Q4 Revenue And New Multiyear Contract Wins

Helix Energy Solutions Group (HLX) is back in focus after reporting its highest fourth quarter revenue since 2013, positive free cash flow, and year end cash and liquidity that support recently secured multiyear contracts. See our latest analysis for Helix Energy Solutions Group. Those results come after a busy period, with Helix Energy Solutions Group reporting full year 2025 earnings, recording a US$18.06 million long lived asset impairment, completing its share repurchase program, and...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Is Oddity Tech (ODD) Now An Opportunity After A 70% Year To Date Share Price Fall

If you are wondering whether Oddity Tech is now a bargain or a value trap, a closer look at how its current share price lines up with its fundamentals can help frame that question. The stock has seen large price swings recently, with a 7 day return of 63.2% decline, a 30 day return of 64.8% decline, and a year to date return of 70.2% decline, while the 1 year return sits at 75.3% decline from the current last close of US$11.77. These moves have prompted renewed attention on the business, as...
NYSE:B
NYSE:BMetals and Mining

Is It Time To Reassess Barrick Mining After Strong 1‑Year Share Price Gains?

If you are wondering whether Barrick Mining is priced attractively today, you are not alone. This article focuses squarely on what the current share price might mean for value‑focused investors. The stock last closed at US$50.76, with returns of 5.8% over 7 days, a 4.2% decline over 30 days, 15.2% year to date, 192.8% over 1 year and 229.7% over 3 years, which can affect how the market currently thinks about its potential and its risks. Recent news around Barrick Mining has highlighted...
NYSE:CTRI
NYSE:CTRIConstruction

Centuri Holdings Backlog And Expansion Put Record 2025 Profits To Test

Centuri Holdings (NYSE:CTRI) reported record revenue and profitability for 2025. The company secured a 59% increase in backlog to $5.9b, supporting 2026 revenue visibility. Centuri announced expansion into new states and maintained a 100% Master Service Agreement renewal rate. Management is adjusting fleet funding and working to reduce seasonality in its gas business. Centuri Holdings enters 2026 with fresh momentum, backed by record 2025 financial results and a growing project book. The...
NYSE:WEX
NYSE:WEXDiversified Financial

Is It Time To Reassess WEX (WEX) After Its Multi‑Year Share Price Slide?

If you are wondering whether WEX at around US$149 per share is offering fair value or a potential bargain, you are not alone in questioning what the current price really reflects. Over shorter periods the stock has been under pressure, with a 5.2% decline over the past week, a 3.5% decline over 30 days, a 5.0% decline over 1 year and a 30.3% decline over 5 years, while the year-to-date return sits at 0.5%. These moves have come as investors continue to reassess payment and fintech related...
NYSE:AWK
NYSE:AWKWater Utilities

American Water Works Invests Over US$1b As Valuation Premium Persists

American Water Works Company (NYSE:AWK) and its subsidiaries have announced multi state infrastructure investment programs exceeding US$1b to upgrade water and wastewater systems. The initiatives focus on modernizing aging infrastructure, improving system reliability, and reducing service disruptions across several regions. The American Water Charitable Foundation has also launched its 2026 grant program to support water, conservation, and environmental education projects in local...
NasdaqGS:OS
NasdaqGS:OSSoftware

OneStream (OS) Turns First Quarterly Profit As Bulls Test Profitability Narrative

OneStream (OS) just closed out FY 2025 with Q4 revenue of US$163.7 million, Basic EPS of US$0.01, and net income of US$1.0 million, set against trailing 12 month revenue of US$601.9 million and a loss of US$50.3 million. The company has seen quarterly revenue move from US$132.5 million in Q4 FY 2024 to US$163.7 million in Q4 FY 2025, while Basic EPS shifted from a loss of US$0.10 to a slight profit of US$0.01 over the same period. This frames a story where top line growth is occurring...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales

BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib. The company reported strong commercial momentum for its product Attruby, supporting a move toward cash generation. Management framed this combination of clinical and commercial news as a pivotal inflection in the business model. BridgeBio Pharma comes into this update with a current share price of $66.445 and a very large 3 year return, alongside a 90.4% return over the past...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

Fortrea Executive Shuffle Seeks Stronger Clinical Focus And Turnaround Potential

Fortrea Holdings (NasdaqGS:FTRE) has reshaped its executive ranks, naming Scott Dove, PhD, as President of Clinical Pharmacology Services. Oren Cohen, MD, is shifting into a more focused position as Chief Medical Officer, concentrating on Fortrea's medical direction. These changes highlight management's attention on clinical research and development within the broader contract research space. For investors watching Fortrea at a share price of $10.71, the company is pairing leadership moves...